DeepToday
Life Biosciences doses first patient in epigenetic aging reversal trial
Life Biosciences dosed the first human in a Phase 1 trial of ER-100, an AAV gene therapy that reprograms retinal cells to reverse aging, moving epigenetic rejuvenation from lab to clinic.